Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-15

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

NCT04985357

Stage III Breast Cancer Stage IV Breast Cancer Stage III Lung Cancer +35 more

WITHDRAWN

Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor

NCT01453465

Childhood Atypical Teratoid/Rhabdoid Tumor Rhabdoid Tumor of the Kidney

WITHDRAWN

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

NCT07327489

Skin Cancer Cancer Immunotherapy +12 more

RECRUITING

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

NCT02245100

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Salivary Gland Squamous Cell Carcinoma Stage IIIA Non-small Cell Lung Cancer +27 more

COMPLETED

Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy

NCT00898430

Head and Neck Cancer

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pleural Effusion, Malignant Ascites, Malignant Carcinoma Carcinoma, Hepatocellular Carcinoma, Renal Cell Carcinoma, Renal Carcinoma, Small Cell Carcinoma, Non-Small-Cell Lung Carcinoma, Pancreatic Ductal Carcinoma, Neuroendocrine Carcinoma, Thymic Carcinoma, Pancreatic Carcinoma Breast Carcinoma, Ovarian Carcinoma Bladder Carcinoma of Unknown Primary Carcinoma of the Head and Neck Carcinoma of the Oropharynx Carcinoma of the Larynx Carcinoma of the Bladder Carcinoma of Esophagus Carcinoma of the Nasopharynx Carcinoma of the Penis Carcinoma of the Cervix Carcinoma of the Anus Carcinoma of the Vulva Carcinoma of the Appendix Carcinoma of the Oral Cavity Cholangiocarcinoma Melanoma Mesothelioma Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient is ≥18 years of age
2. Written Informed Consent provided by patient
3. Diagnosis of any kind of carcinoma
4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
5. Proceeding onto therapy for treatment
6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)